Clinical Trials Directory

Trials / Completed

CompletedNCT04918407

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Effects of Empagliflozin in Reducing Oxidative Stress of Diabetic Recipients After Kidney Transplantation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Shahid Beheshti University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes after kidney transplantation. The association is examined by comparing the difference in oxidative modifications before and after 90 days treatment with 25 mg empagliflozin plus insulin compared to insulin treatment. The study is randomised and double-blinded. Each treatment group consists of 20 patients. Oxidative stress markers are measured by serum level of superoxide dismutase activity ,lipid peroxidation assay kit, glutathione assay, glutathione peroxidase activity , total antioxidant capacity assay oxidant status , carbonyl content assay and bca protein assay . . A student t-test will be performed to compare adding empagliflozin . The results will be published in a peer-review journal.

Detailed description

With the purpose of studying the antioxidant activity of empagloflozin 25mg will add on insulin in 20 patients after kidney transplant and will compare with 20 diabetic recipient of kidney transplant on insulin therapy alone.

Conditions

Interventions

TypeNameDescription
DRUGEmpagliflozin 25 MG25 mg
DRUGInsulinInsulin

Timeline

Start date
2022-01-01
Primary completion
2025-07-05
Completion
2025-08-05
First posted
2021-06-08
Last updated
2025-09-08

Locations

2 sites across 1 country: Iran

Source: ClinicalTrials.gov record NCT04918407. Inclusion in this directory is not an endorsement.